Report cover image

Macular Degeneration Drug Pipeline Analysis Report 2025

Publisher Expert Market Research
Published May 25, 2025
Length 200 Pages
SKU # EMAR20146970

Description

A study conducted in 2022 revealed that around 19.83 million Americans were affected by some form of age-related macular degeneration (AMD). Out of these, around 1.49 million people were affected by late-stage AMD. The prevalence of developing the condition increases with age. It rises from 2% (for people aged 40 to 44 years) to 46.6% (for people aged above 85). As the global geriatric population is growing, the demand for high-efficacy macular degeneration drugs is on the rise. This has prompted major healthcare institutions to develop new drugs, resulting in an increased number of drugs in the pipeline.

Report Coverage

The Macular Degeneration Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into macular degeneration therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for macular degeneration. The macular degeneration report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The macular degeneration pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with macular degeneration treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to macular degeneration.

Macular Degeneration Drug Pipeline Outlook

Age-related macular degeneration (AMD) is a condition which damages a part of the retina (macula), leading to loss of central vision. It is commonly divided into two categories, namely, dry AMD and wet AMD. Dry age-related macular degeneration involves thinning of the macula with age and formation of drusen (small protein clumps). It is more common as compared to wet AMD. The American Academy of Ophthalmology reports that 8 out of 10 people are affected by dry AMD. Although less common, wet AMD is considered to be more serious as vision loss is faster in comparison to dry AMD. It involves the growth of new and abnormal blood vessels under the retina. These blood vessels may leak and scar the macula significantly.

Macular degeneration treatment involves the use of anti-VEGF therapies, which work by inhibiting abnormal vessel growth and decreasing the chance of fluid leakage. Photodynamic therapy and laser photocoagulation can also be used based on patient profiles. In 2023, two new drugs Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol) received the U.S. FDA’s approval for geographic atrophy (a late stage of dry AMD) treatment. These intravenous drugs slowed disease progression by about 14% to 20%.

For years, patients have been limited to using AREDS2 vitamins for treating intermediate stages of dry AMD. However, the approval of new drugs elevates hope for both patients and healthcare professionals to manage the condition more efficiently.

Macular Degeneration – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of macular degeneration drug candidates based on various segmentations such as:

By Phase

EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products
By Drug Class

EMR’s pipeline assessment report covers 50+ drug analyses based on drug classes:
  • Anti-VEGF (Vascular Endothelial Growth Factor) Agents
  • Anti-Inflammatory Agents
  • Complement Inhibitors
By Route of Administration

EMR’s macular degeneration report assessment covers 50+ drug analyses based on the route of administration.
  • Oral
  • Parenteral
  • Others
Macular Degeneration – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total clinical trials conducted, with over 550 macular degeneration emerging drugs undergoing clinical development.

Macular Degeneration – Pipeline Assessment Segmentation, By Drug Class

The drug class categories covered under macular degeneration pipeline analysis include anti-VEGF (vascular endothelial growth factor) agents, anti-inflammatory agents (corticosteroids), complement inhibitors and others. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials. According to EMR analysis, gene therapy, stem cell therapy and other photodynamic therapies are under investigation and likely to impact the drug class landscape significantly in coming years.

Macular Degeneration Clinical Trials Assessment – Competitive Dynamics

The EMR report for the macular degeneration drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed macular degeneration therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in macular degeneration clinical trials:
  • CHABiotech CO., Ltd
  • F. Hoffmann-La Roche AG
  • GSK Plc.
  • Allegro Ophthalmics, LLC
  • Bayer AG
  • IVERIC Bio, Inc.
  • Allergan Inc.
  • Others
Macular Degeneration – Emerging Drugs Profile

GT005

This investigational gene therapy is currently under phase 2 clinical trials of a program initiated by The Department of Ophthalmology at Columbia University Irving Medical Center. It acts on the complement factor I (CFI) protein that inhibits the immune system from attacking the retina cells. This intravenous drug intended to treat geographic atrophy secondary to dry age-related macular degeneration has also received Fast-Track Designation from the United States FDA.

Ixo-vec

Developed by Adverum Biotechnologies Inc., this macular degeneration drug candidate showed efficacy in over 90% of the subjects in the LUNA Phase 2 trial. This trial involves 60 patients with wet AMD and is divided across two dose cohorts 2E11 and 6E10 vg/eye. Both doses involved showed visual as well as anatomic outcomes, signifying its efficacy.

4D-150

4D Molecular Therapeutics’ wet AMD drug candidate 4D-150 showed positive outcomes in Phase 2 PRISM clinical trial. This trial evaluated the safety, durability, and suitability of the drug. The company aims to present the drug for Phase 3 and apply for FDA RMAT and EMA PRIME designations as well.

CT-1812

Sponsored by Cognition Therapeutics, this drug is under evaluation to treat late-stage dry AMD. CT-1812 is a small-molecule oral medication that has the potential to cross the blood-retinal barrier and reach the back of the retina without injection intervention. The drug will be evaluated on 246 patients as a part of the Phase 2 MAGNIFY study.

Reasons To Buy This Report

The Macular Degeneration Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for macular degeneration. It provides the necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities provided by the macular degeneration drug report.

Key Questions Answered in the Macular Degeneration – Pipeline Assessment Report
  • What is the current landscape of systemic macular degeneration drugs?
  • Which companies/institutions are developing macular degeneration therapeutic drugs?
  • How many phase II drugs are currently present in macular degeneration pipeline drugs?
  • Which company is leading the macular degeneration pipeline development activities?
  • What is the current macular degeneration commercial assessment?
  • What are the opportunities and challenges present in the macular degeneration drug pipeline landscape?
  • What is the efficacy and safety profile of macular degeneration pipeline drugs?
  • Which companies/institutions are involved in macular degeneration collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What geographies are covered for clinical trials in macular degeneration?
Related Reports

Age-Related Macular Degeneration Market

Neovascular Age-Related Macular Degeneration Market

Table of Contents

200 Pages
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology and Assumptions
2 Executive Summary
3 Overview of Macular Degeneration
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Types of Macular Degeneration
3.5 Diagnosis
3.6 Treatment
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Macular Degeneration: Epidemiology Snapshot
5.1 Macular Degeneration Incidence by Key Markets
5.2 Macular Degeneration– Patients Seeking Treatment in Key Markets
6 Macular Degeneration: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Macular Degeneration: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Macular Degeneration, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Macular Degeneration Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Macular Degeneration Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Anecortave Acetate
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Ranibizumab
10.2.3 Aflibercept
10.2.4 Other Drug
11 Macular Degeneration Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 MA09-hRPE
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Anecortave Acetate
11.2.3 Avacincaptad Pegol
11.2.4 Other Drugs
12 Macular Degeneration Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 ALG 1001
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 AdGVPEDF.11D
12.2.3 BI 754132
12.2.4 Other Drugs
13 Macular Degeneration Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 HG202
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 BD311
13.2.3 MB-102
13.2.4 Other Drugs
14 Macular Degeneration, Key Drug Pipeline Companies
14.1 CHABiotech CO., Ltd
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 F. Hoffmann-La Roche AG
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 GSK Plc.
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Allegro Ophthalmics, LLC
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Bayer AG
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 IVERIC bio, Inc.
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
14.7 Allergan Inc.
14.7.1 Company Snapshot
14.7.2 Pipeline Product Portfolio
14.7.3 Financial Analysis
14.7.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us